Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?
Evan Stein, ESC, August 31, 2013
The symposium PCSK9: the new lipid target in preventive cardiology? was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013. A videopresentation from the lecture by Evan Stein Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling? is now available on this website.
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.